2022年1月22日 · This breakthrough combination and schedule of drugs for AML, widely known as the “7 and 3” regimen, dramatically changed the prognosis of patients, has remained the backbone of standard therapy for close to five decades, and, amazingly, is still going strong.

4 天之前 · In vitro and in vivo studies involving AML cell lines, patient samples and murine xenografts exhibited sensitivity to treatment with Ven in the low nanomolar range (0.001–1 µg/ml) [4].

7 + 3 chemotherapy is given to eliminate leukemia cells from the body and to decrease symptoms from AML, such as bleeding, bruising and recurrent infections. 7+3 is commonly given with the goal of cure.

AML亚型 急性早幼粒细胞白血病 （APL）有不同的治疗方法。 急性髓细胞白血病的治疗通常需要在确诊后尽快开始，因为它的进展非常快。

2023年8月26日 · Our findings shed light on the pathogenesis of -7/del7q MNs, while 27 potential synthetic lethal target genes and 26 differential expressed genes allow for a therapeutic window of -7/del7q.

2025年1月24日 · 7+3方案是AML患者常用的诱导治疗方案，包括7天的阿糖胞苷（Ara-C）和3天的柔红霉素（DNR）或伊达比星（IDA）。 对于有利风险组的患者，通常采用此方案进行治疗。

2022年4月11日 · 核心结合因子相关急性髓系白血病（CBF-AML）在强化治疗下预后相对较好，治疗方案通常包括7天连续静脉 (IV)阿糖胞苷和3天蒽环类药物IV推注 (“7 + 3”)，随后多个周期的高剂量阿糖胞苷巩固治疗。

2024年11月3日 · 急性髓系白血病（AML）-NCCN指南（2024年第一版）已公布，较之于2023年第6版的内容进行了较大的修订，在治疗方面，针对AML强化诱导治疗、基于阿糖胞苷诱导后的随访和再诱导治疗、巩固治疗和维持治疗等方面进行了较大程度的更新。

2025年3月20日 · For decades, the only option for newly diagnosed acute myelogenous leukemia (AML) that provided a path to remission and long-term disease-free survival required initial treatment with intensive induction therapy. Anthracycline- and cytarabine-based regimens were the sole standard of care globally. Diagnosis and prognosis were based only on morphology and cytogenetics. Prolonged hospitalization ...

2025年3月20日 · Treatment for patients with acute myeloid leukemia (AML) is being transformed for some patients, as targeted agents increase complete remission rates and s